Head-to-head evidence
SHR-1139 vs spesolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-36 receptor · full Psoriasis pipeline
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
spesolimab · Spevigo (approved elsewhere, for GPP)
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT03886246 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR-1139's landscape · spesolimab's landscape